EE359 US Cost-Effectiveness of Chimeric Antigen Receptor T-Cell (CAR T) Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL), Considering Infusion Setting and Payor Claims Data
Abstract
Authors
AK Cummings Joyner J Snider S Wade ST Wang MG Buessing S Johnson U Gergis